ARO-DIMERPA / Arrowhead Pharmaceuticals - LARVOL DELTA

First-in-Human Trial of a Dual Functional RNAi Molecule to Silence Expression of Both PCSK9 and APOC3 in Mixed Hyperlipidemia (AHA 2026) - No abstract available

First-in-human • Late-breaking abstract • P1 data • Dyslipidemia • Mixed Hyperlipidemia • PCSK9

Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia (clinicaltrials.gov) - P1/2 | N=78 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Trial primary completion date: Jun 2026 ➔ Sep 2026

Trial primary completion date • Dyslipidemia • Mixed Hyperlipidemia

Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia (clinicaltrials.gov) - P1/2 | N=78 | Not yet recruiting | Sponsor: Arrowhead Pharmaceuticals

New P1/2 trial • Dyslipidemia • Mixed Hyperlipidemia

Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia (clinicaltrials.gov) - P1/2 | N=78 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Not yet recruiting ➔ Recruiting | Trial primary completion date: Jul 2027 ➔ Jun 2026

Enrollment open • Trial primary completion date • Dyslipidemia • Mixed Hyperlipidemia